Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07456761

Effect of Low-dose Pregabalin Retard (82.5 mg) Versus Standard-dose Pregabalin Retard (165 mg) on Postoperative Pain and Opioid Consumption After Elective Laparoscopic Abdominal Surgery

Effect of Low-dose Pregabalin Retard (82.5 mg) Versus Standard-dose Pregabalin Retard (165 mg) on Postoperative Pain and Opioid Consumption After Elective Laparoscopic Abdominal Surgery: a Randomized, Double-blind, Controlled Trial

Status
Not Yet Recruiting
Phase
N/A
Study type
Interventional
Enrollment
80 (estimated)
Sponsor
South Egypt Cancer Institute · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The goal of this clinical trial is to detect whether pregabalin retard (82.5 mg or 165 mg) improves analgesia after elective laparoscopic abdominal surgery in adults. It will also evaluate the safety of both doses. The main questions it aims to answer are: Does the higher dose (165 mg) reduce the total amount of opioids needed in the first 24 hours after surgery compared to the lower dose (82.5 mg)? Do the pain scores differ between the two doses? Are there differences in side effects between the two doses? Researchers will compare two different doses of pregabalin retard to determine which provides better pain control with fewer side effects. Participants will: Take one dose of pregabalin retard (82.5 mg or 165 mg) before surgery Receive standard anesthesia and multimodal pain treatment Have their pain levels and opioid use monitored for 24 hours after surgery Be assessed for side effects such as dizziness, nausea, or sedation

Conditions

Interventions

TypeNameDescription
DRUGPregabalin retard 82.5 mgOral Administration 1-2 hours before elective laparoscopic abdominal surgery
DRUGPregabalin retard 165 mgOral Administration 1-2 hours before elective laparoscopic abdominal surgery

Timeline

Start date
2026-04-01
Primary completion
2026-11-01
Completion
2026-12-01
First posted
2026-03-06
Last updated
2026-04-02

Source: ClinicalTrials.gov record NCT07456761. Inclusion in this directory is not an endorsement.